REVEAL pulmonary arterial hypertension (PAH) risk score.

Slides:

Advertisements

Similar presentations

Pulmonary hypertension Goal directed therapy Pulmonary Hypertension Programme University of Toronto FMD.

Advertisements

REVEAL Registry PAH Risk Score Calculator

Pulmonary arterial hypertension due to pulmonary veno-occlusive disease in systemic sclerosis: Importance of early diagnosis and cautious use of pulmonary.

Volume 141, Issue 2, Pages (February 2012)

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

ECG: electrocardiogram; PFT: pulmonary function testing; Dlco: diffusion capacity of the lung for carbon monoxide; BGA: blood gas analysis; HRCT: high-resolution.

Disease progression is preceded by right ventricular remodelling, but not by changes in clinical parameters. Disease progression is preceded by right ventricular.

Diagnostic algorithm for pulmonary arterial hypertension (PAH).

Cohort identification and exclusion.

Volume 146, Issue 6, Pages (December 2014)

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Diagnostic algorithm. Diagnostic algorithm. PH: pulmonary hypertension; group: clinical group; TTE: transthoracic echocardiography; PFT: pulmonary function.

Algorithm for the diagnosis and treatment of portopulmonary hypertension (POPH). Algorithm for the diagnosis and treatment of portopulmonary hypertension.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Michael D. McGoon, MD, Abby Krichman, RRT, Harrison W

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Cox proportional hazard estimates for multivariate model of survival, limited to terms included in the final stepwise model. Cox proportional hazard estimates.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

An expert proposal for a treat-to-target checklist for pulmonary arterial hypertension (PAH). An expert proposal for a treat-to-target checklist for pulmonary.

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

Micha T. Maeder, MD, PhD, Niklas F. Ehl, MD

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

Predicting Survival in Patients With Pulmonary Arterial Hypertension

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Prevalence of different aetiologies of pulmonary hypertension (PH) in the paediatric population (results from national registries and paediatric cohorts).

Elastic staining of paraffin-embedded lung tissue.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

A pump function graph demonstrating mean right ventricular pressure as a function of stroke volume (SV). A pump function graph demonstrating mean right.

How to Screen for PAH in Scleroderma-Spectrum Disorders

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

Mean pulmonary arterial pressure (Ppa) as a function of cardiac output (Q) at two different levels of pulmonary vascular resistance (PVR). Mean pulmonary.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

A) Pulmonary arterial hypertension (PAH) aetiological breakdown of REVEAL patients at enrolment. b) Breakdown of associated PAH subgroup. a) Pulmonary.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Algorithm for haemodynamic evaluation in the elderly.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Distribution of diffusing capacity of the lung for carbon monoxide (DLCO) among 243 scleroderma patients who underwent right heart catheterisation (RHC)

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Endobronchial valve (EBV) treatment for emphysema, summary of treatment selection and outcome. Endobronchial valve (EBV) treatment for emphysema, summary.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Survival estimates of patients in REVEAL using Kaplan–Meier estimates stratified by newly versus previously diagnosed patients and survival estimated by.

Schematic diagram of the DETECT study [56].

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

REVEAL pulmonary arterial hypertension (PAH) risk score. REVEAL pulmonary arterial hypertension (PAH) risk score. CTD: connective tissue disease; APAH: associated PAH; PoPH: portal hypertension; FPAH: familial PAH; WHO: World Health Organization; NYHA: New York Heart Association; 6MWD: 6-min walk distance; BNP: brain natriuretic peptide; PFT: pulmonary function test; RHC: right heart catheterisation; SBP: systolic blood pressure; HR: heart rate; DL,CO: diffusing capacity of the lung for carbon monoxide; % pred: % predicted; P̄ra: mean right atrial pressure; PVR: pulmonary vascular resistance. #: if N-terminal proBNP is available and BNP is not, cut-off points are replaced with <300 pg·mL−1 and >1,500 pg·mL−1. Reproduced from [31] with permission from the publisher. M.D. McGoon, and D.P. Miller Eur Respir Rev 2012;21:8-18 ©2012 by European Respiratory Society